CRISPR-Cas9–Mediated Modification of the NOD Mouse Genome With Ptpn22(R619W) Mutation Increases Autoimmune Diabetes

An allelic variant of protein tyrosine phosphatase nonreceptor type 22 (PTPN22), PTPN22(R620W), is strongly associated with type 1 diabetes (T1D) in humans and increases the risk of T1D by two- to fourfold. The NOD mouse is a spontaneous T1D model that shares with humans many genetic pathways contri...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Xiaotian, Pelletier, Stephane, Gingras, Sebastien, Rigaud, Stephanie, Maine, Christian J., Marquardt, Kristi, Dai, Yang D., Sauer, Karsten, Rodriguez, Alberto R., Martin, Greg, Kupriyanov, Sergey, Jiang, Ling, Yu, Liping, Green, Douglas R., Sherman, Linda A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2016
Materias:
Technological Advances
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955979/
https://www.ncbi.nlm.nih.gov/pubmed/27207523
http://dx.doi.org/10.2337/db16-0061
Descripción
Sumario:An allelic variant of protein tyrosine phosphatase nonreceptor type 22 (PTPN22), PTPN22(R620W), is strongly associated with type 1 diabetes (T1D) in humans and increases the risk of T1D by two- to fourfold. The NOD mouse is a spontaneous T1D model that shares with humans many genetic pathways contributing to T1D. We hypothesized that the introduction of the murine orthologous Ptpn22(R619W) mutation to the NOD genome would enhance the spontaneous development of T1D. We microinjected CRISPR-Cas9 and a homology-directed repair template into NOD single-cell zygotes to introduce the Ptpn22(R619W) mutation to its endogenous locus. The resulting Ptpn22(R619W) mice showed increased insulin autoantibodies and earlier onset and higher penetrance of T1D. This is the first report demonstrating enhanced T1D in a mouse modeling human PTPN22(R620W) and the utility of CRISPR-Cas9 for direct genetic alternation of NOD mice.

Ejemplares similares